National Veterinary Scholars Symposium Highlights Importance Of One-Health Expertise And Perspective To Next Generation Of Veterinarians And Scientists
DULUTH, Ga., Aug. 6, 2021 /PRNewswire/ -- Nearly 900 veterinary students and leaders from three dozen veterinary schools in the U.S. convened virtually this week for the annual National Veterinary Scholars Symposium. They learned from researchers, public health officials and industry experts about the global burden of disease, infectious disease control and potential pathways for research careers – such as in emerging and transboundary diseases – where their veterinary training and One Health perspective is critical.
In addition, several students were recognized with Boehringer Ingelheim Research Awards for Graduate Veterinarians and Veterinary Students. Winning students receive monetary prizes and a stipend to attend the Symposium to accept their awards and present their research.
Dr. Brittany Szafran, from Mississippi State's College of Veterinary Medicine, received the 2021 Boehringer Ingelheim Veterinary Research Award for Graduate Veterinarians, which promotes research in veterinary biosciences. It recognizes graduate veterinarians who have completed or will soon complete a Ph.D. program or are in their final years of residency training in veterinary pathology, medicine, surgery, radiology/ imaging, or laboratory animal medicine. Dr Szafran's work has focused on the underlying biochemical and immunologic mechanisms in response to pesticides to better understand and help protect the health of people, animals, and the environment from the potential toxicity of chemicals.
Carley Allen, from the University of Missouri College of Veterinary Medicine, received the 2021 Boehringer Ingelheim Veterinary Research Award for Veterinary Students. Allen's research has focused on investigating a novel molecular target for inhibiting cell growth and improving survival in canine osteosarcoma, the most common skeletal malignancy of dogs and a beneficial comparative and translational model for human osteosarcoma.
Brittany Allen, from Ohio State University's College of Veterinary Medicine, and Jaqueline Chevalier, from Cornell University's College of Veterinary Medicine, also received recognition as honorable mention Boehringer Ingelheim Veterinary Research Scholars.
The annual National Veterinary Scholars Symposium was hosted this year by Iowa State University's College of Veterinary Medicine, and sponsored by Boehringer Ingelheim, the American Association of Veterinary Medical Colleges, the American Veterinary Medical Association and the National Institutes of Health. The symposium showcases research conducted by veterinary students in the course of their Veterinary Scholar Program research internships.
"These students are joining the life sciences field at a remarkable time. The frequency of pandemics and transboundary threats is predicted to increase, presenting new and greater risks to human and animal health, as well as our food supply," Caroline Belmont, head of U.S. Animal Health Innovation for Boehringer Ingelheim, said in a welcome address to participants. "The One Health perspectives and capabilities of today's veterinary students will undoubtedly play a critical role in addressing our future challenges, and the hands-on experience, guidance and support we provide them now represents an important investment in the future health of animals and humans."
The Boehringer Ingelheim Veterinary Scholars Program was established more than 30 years ago to introduce first- and second-year veterinary medical students to biomedical research. At each participating school, Boehringer Ingelheim Veterinary Scholars are assigned a mentor and laboratory. Each scholar conducts a hypothesis-driven research project. The research project is typically conducted over a 10-12-week period during the summer, with students presenting their work at the conclusion. Nearly 5,000 students have received stipends from Boehringer Ingelheim to conduct research since the program started. More information is available at http://veterinaryscholars.boehringer-ingelheim.com/.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 9,700 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment guides us every day. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of $4.7 billion (4.1 billion euros) in 2020 and presence in more than 150 countries.
Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim has been independent and family owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, with around 52,000 employees, we create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
In 2020, Boehringer Ingelheim achieved net sales of around $22.33 billion (19.57 billion euros). Our significant investment of over $4.2 billion (3.7 billion euros) in 2020 (18.9% of net sales) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
SOURCE Boehringer Ingelheim, Inc.
Share this article